At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Study of SAPIEN 3 Transcatheter Heart Valve Implantation in Patients with a Failing Aortic Bioprosthetic Valve

Clinical Trial Title: 
PARTNER 3 AVIV: A prospective, single-arm, multicenter study to investigate the safety and effectiveness of SAPIEN 3 transcatheter heart valve implantation in patients with a failing aortic bioprosthetic valve.
Clinical Trial Protocol ID: 
17052501
Clinical Trial Investigator Name: 
Clifford J. Kavinsky, MD, PhD
Clinical Trial Protocol Description: 

The purpose of this study is to assess the safety and effectiveness of the SAPIEN 3 transcatheter heart valve in patients with a failing transcatheter aortic bioprosthetic valve.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have failing transcatheter aortic bioprosthetic valve with ≥ moderate stenosis and/or ≥ moderate insufficiency.
  • Have bioprosthetic valve with an internal orifice diameter of 16mm to 27mm.
  • Have NYHA Functional Class ≥ II.

You will be excluded from the study if any of the following criteria apply to you:

  • Have any paravalvular leak (PVL) in the aortic bioprosthetic valve.
  • Need any concomitant revascularization for coronary artery disease (CAD).
  • Have EF < 30% and eGFR < 30.
  • Have severe regurgitation (>3+) or stenosis of any other valve.

This is a partial list of inclusion and exclusion criteria. To inquire about your eligibility, please call the contact number provided.

Clinical Trial Area: 
Heart and Vascular Conditions
Contact Phone: 
(312) 942-9398
Contact Name: 
Deanna Aubry